OKLAHOMA Health Care Authority

State of Oklahoma
SoonerCare
Tibsovo® (Ivosidenib) Prior Authorization Form

Member Name:_____ ***Date of Birth:***_____ ***Member ID#:***_____

Drug Information

Pharmacy Billing (NDC:_____***) Start Date (or date of next dose):***_____

Dose:_____ ***Regimen:***_____

Billing Provider Information

Pharmacy NPI:_____ ***Pharmacy Name:***_____

Pharmacy Phone:_____ ***Pharmacy Fax:***_____

Prescriber Information

Prescriber NPI:_____ ***Prescriber Name:***_____

Prescriber Phone:_____ ***Prescriber Fax:***_____ ***Specialty:***_____

Criteria

For Initial Authorization:

1. Please indicate the diagnosis and information:

☐ **Acute Myeloid Leukemia (AML)**
- A. Is AML newly-diagnosed? Yes☐ No☐
  - i. If member is younger than 75 years of age, are they unable to tolerate intensive induction chemo-therapy? Yes☐ No☐
  - ii. Has an IDH1 mutation been detected? Yes☐ No☐
  - iii. Will Tibsovo® (ivosidenib) be used as a single-agent or in combination with azacitidine? Yes☐ No☐
- B. Is AML relapsed or refractory? Yes☐ No☐
  - i. Will Tibsovo® (ivosidenib) be used as a single-agent? Yes☐ No☐
  - ii. Has an IDH1 mutation been detected? Yes☐ No☐

☐ **Cholangiocarcinoma**
- A. Is diagnosis locally advanced or metastatic cholangiocarcinoma? Yes☐ No☐
- B. Has an IDH1 mutation been detected? Yes☐ No☐
- C. Has the member received prior treatment for this diagnosis? Yes☐ No☐

☐ **Myelodysplastic Syndromes (MDS)**
- A. Is diagnosis relapsed or refractory MDS? Yes☐ No☐
- B. Is there presence of isocitrate dehydrogenase-1 (IDH1) mutation, as detected by an FDA-approved test? Yes☐ No☐

☐ **If answer is none of the above, please indicate diagnosis:**_____

Additional Information:_____

_____

For Continued Authorization:

1. Date of last dose:_____
2. Does member have any evidence of progressive disease while on ivosidenib? Yes☐ No☐
3. Has the member experienced adverse drug reactions related to ivosidenib therapy? Yes☐ No☐

*If yes, please specify adverse reactions:*_____

_____

Prescriber Signature:_____ **Date:**_____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. *Failure to complete this form in full will result in processing delays.*

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy
Pharmacy Management Consultants
Product Based Prior Authorization Unit

Fax: 1-800-224-4014
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

DRAFT